Disease-modifying drugs in Alzheimer's disease
نویسندگان
چکیده
منابع مشابه
Disease-modifying drugs in Alzheimer’s disease
Alzheimer's disease (AD) is an age-dependent neurodegenerative disorder and the most common cause of dementia. The early stages of AD are characterized by short-term memory loss. Once the disease progresses, patients experience difficulties in sense of direction, oral communication, calculation, ability to learn, and cognitive thinking. The median duration of the disease is 10 years. The pathol...
متن کاملBiologic Disease-Modifying Antirheumatic Drugs
1. Distinguish between biologic DMARD use and nonbiologic DMARD use in the treatment of rheumatoid arthritis (RA). 2. Assess the differences between classes of biologic disease-modifying antirheumatic drug (DMARD) therapy. 3. Based on individual patient characteristics, construct a treatment and monitoring plan for a patient with RA and, when appropriate, include biologic DMARD therapy. 4. Just...
متن کاملDisease-modifying Antirheumatic Drugs (DMARDs)
Therapy with disease-modifying antirheumatic drugs (DMARDs) should be started as soon as the diagnosis of rheumatoid arthritis (RA) is made. [1]The early use of DMARDs has been recommended in recent years to reduce disease progression and long-term disability. [2]The need for early use of DMARDs is incorporated in new National Institute for Health and Care Excellence (NICE) guidance. [3]Early u...
متن کاملDisease-modifying Antirheumatic Drugs (DMARDs)
Therapy with disease-modifying antirheumatic drugs (DMARDs) should be started as soon as the diagnosis of rheumatoid arthritis (RA) is made. [1]The early use of DMARDs has been recommended in recent years to reduce disease progression and long-term disability. [2]The need for early use of DMARDs is incorporated in new National Institute for Health and Care Excellence (NICE) guidance. [3]Early u...
متن کاملDisease-modifying Antirheumatic Drugs (DMARDs)
Therapy with disease-modifying antirheumatic drugs (DMARDs) should be started as soon as the diagnosis of rheumatoid arthritis (RA) is made. [1]The early use of DMARDs has been recommended in recent years to reduce disease progression and long-term disability. [2]The need for early use of DMARDs is incorporated in new National Institute for Health and Care Excellence (NICE) guidance. [3]Early u...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Drug Design, Development and Therapy
سال: 2013
ISSN: 1177-8881
DOI: 10.2147/dddt.s41431